Adial pharmaceuticals announces positive in vivo data for purnovate's pnv-5032 as a potential treatment for asthma

Charlottesville, va., feb. 09, 2022 (globe newswire) -- purnovate, inc., a wholly owned subsidiary of adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), today announced positive in vivo data for pnv-5032, as a potential treatment for asthma. pnv-5032 demonstrated a significant inhibition of pulmonary flow resistance, which is a measure of asthmatic response, in an in vivo model.
ADIL Ratings Summary
ADIL Quant Ranking